Difference between revisions of "Sirolimus (Rapamune)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | mTOR | + | From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=42555 NCI Drug Dictionary]: A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Histiocytoses|Erdheim-Chester disease]] | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
| + | |||
| + | ==Also known as== | ||
| + | AY 22989, RAPA, Rapamycin, SILA 9268A, SLM, WY-090217 | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| Line 12: | Line 16: | ||
[[Category:mTOR inhibitors]] | [[Category:mTOR inhibitors]] | ||
| + | [[Category:Histiocytoses medications|Erdheim-Chester disease medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Drugs FDA approved in 1999]] | [[Category:Drugs FDA approved in 1999]] | ||
Revision as of 19:59, 24 September 2015
Mechanism of action
From the NCI Drug Dictionary: A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production.
Diseases for which it is used
Also known as
AY 22989, RAPA, Rapamycin, SILA 9268A, SLM, WY-090217